Intel

Intel’s Insights from BioData World Congress 2016

One of our sponsors at BioData World Congress– Intel, prepared a post- event article with insights on the most burning topics that were discussed last week. Last week I was pleased to join a host of partners, customers and industry experts at the leafy Genome Campus in Cambridge, UK, for this year’s BioData World Congress. As one of the world’s leading …

Pfizer acquisition of cancer drug company could advance oncology research

Published Online: Aug 23,2016 Laurie Toich, Assistant Editor Pfizer recently announced its plans to acquire Medivation, a biopharmaceutical company that develops molecules for oncology. Recent health insurer mergers could have deterred the $14 billion deal, but Pfizer and Medivation’s boards of directors approved the merger, and expect that shares will increase immediately, according to a press release from Pfizer. “The proposed …

Interview: Veterans Affairs Precision Oncology Project

Our supporting partner DNAdigest got in touch with one of our speakers at BioData World Congress– Louis Fiore, doctor, scientist, manager, innovator at the Department of Veterans Affairs (VA) in Boston Massachusetts, Executive Director of the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC). Louis will be speaking about the Precision Oncology Project at BioData World Congress USA 2016. We want to share some …

Preview agenda announcement - Americas Antibody Congress

Announcing the release of the preview agenda – Americas Antibody Congress

The preview agenda for Americas Antibody Congress 2016 is now LIVE. Download the preview agenda here > Join us in San Diego next May for an expanded two-day event and deeper content than ever before in: Antibody Engineering Oncology Infectious Diseases ADCs/Bioconjugates Download the preview agenda here to find out more about the content on offer > That’s four full …

Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy

Combination Immunotherapy Significantly More Effective than Ipilimumab Alone for Patients with Advanced Melanoma

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are reporting exciting results in the field of cancer immunology. Positive results from a clinical trial published recently in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second …

NHS faces backlash over Cancer Drugs Fund treatments changes

NHS England announced this week a decision to reassess 42 drugs that are available as part of the Cancer Drugs Fund. The decision comes as a result of current spending expected to be £100m over the initial budget of £280m for this financial year. With the current system viewed as unsustainable, price caps have been brought in for the first time …

Pharma M&A Stocks Soaring due to Glaxo and Novartis deal

Pharma M&A activity spurring stocks higher and higher

UK Stocks in Novartis, AstraZeneca and GlaxoSmithKline rose for a third day yesterday, amid Glaxo’s transaction with Novartis and rumors of a takeover of AstraZeneca by Pfizer. It seems that investors are focusing on the pharmaceuticals M&A industry to shore up global stock markets.   As reported in The Guardian the drugs industry was gripped by ‘merger and acquisition fever’ …

Rate of drug approvals dips down: Nature Study

From year 2003 till 2011, the number of drugs that successfully gets approved as it moves from phase 1 clinical trials to FDA has decreased significantly. Only one in ten has been approved as compared to one in five based on previous year reports. This phenomenon can be attributed to the fact that successful drug approval takes into account the …

Download: Adapting Market Access to New Challenges in Oncology

  At Pharma Pricing & Market Access Europe 2013, key people in the field of pharma marketing discussing topics from maneuvering changes in the healthcare environment to pricing & market access in the major international markets and patient access and flexible pricing schemes. Among the many other speeches and discussions, Ipsen’s SVP Market Access & Pricing, Sylvie Gabriel’s presentation entitled …